RICHMOND HILL, ON / ACCESSWIRE / March 16, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company") today announces, with great sadness, the sudden passing of its Interim Chief Executive Officer and Chairman of the Board of Directors (the "Board"), Prof. Dr. S Slawomir Majewski.
Dr. Majewski has been on the Board since 2012 and has led the Company as its Interim Chief Executive since September 2021. He had been Head of the Department of Dermatology and Venereology, Warsaw Medical University, Poland, since 1998 and was previously Deputy Rector for Science and International Relations at the Medical University of Warsaw and Coordinator of the Polish Center of Preclinical Studies and Technology. He also previously served as member of the Scientific Advisory Board at the Polish Ministry of Health.
"Slawek was an exceptional executive - but more importantly - he was an exceptional human being. He really put patients first both in his practice and at Helix, empowering patients to live healthier lives. He had an uncanny ability of connecting with patients and deriving their unmet needs that he brought into the business discussion at Helix for the past 10 years. Our heartfelt condolences to his family - we all will miss him dearly. May his soul rest in peace." said Artur Gabor, on behalf of the Board.
The Board is currently considering the Company's options with respect to the potential appointment of one or more individuals to assume Dr. Majewski's responsibilities as Interim Chief Executive Officer. The Board also continues the process of identifying a permanent candidate for the position of Chief Executive Officer.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer based on our proprietary technological platform DOS47. Helix is listed on the TSX under the symbol "HBP".
For more information, please contact:
Helix BioPharma Corp.
9120 Leslie Street, Suite 205
Richmond Hill, Ontario, L4B 3J9
Tel: 905-841-2300 x 233
Frank Michalargias, Chief Financial Officer
ir@helixbiopharma.com
Forward-Looking Statements and Risks and Uncertainties
This news release contains forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the Company's future business, operations, research and development, including the Company's activities relating to DOS47, and statements regarding the identification and appointment of a permanent Chief Executive Officer. Forward-looking statements can further be identified by the use of forward-looking terminology such as "ongoing", "estimates", "expects", or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions "will", "may", "could", or "should" occur or be achieved, or comparable terminology referring to future events or results.
Forward-looking statements are statements about the future and are inherently uncertain and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements, including financial outlooks, are intended to provide information about management's current plans and expectations regarding future operations, including without limitation, future financing requirements, and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release.
The Company's actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including without limitation; the risk that the Company's assumptions may prove to be incorrect; the risk that additional financing may not be obtainable in a timely manner, or at all, and that clinical trials may not commence or complete within anticipated timelines or the anticipated budget or may fail; third party suppliers of necessary services or of drug product and other materials may fail to perform or be unwilling or unable to supply the Company, which could cause delay or cancellation of the Company's research and development activities; necessary regulatory approvals may not be granted or may be withdrawn; the Company may not be able to secure necessary strategic partner support; general economic conditions, intellectual property and insurance risks; changes in business strategy or plans; and other risks and uncertainties referred to elsewhere in this news release, any of which could cause actual results to vary materially from current results or the Company's anticipated future results. Certain of these risks and uncertainties, and others affecting the Company, are more fully described in the Company's annual management's discussion and analysis for the year ended July 31, 2021 under the heading "Risks and Uncertainties" and Helix's Annual Information Form, in particular under the headings "Forward-looking Statements" and "Risk Factors", and other reports filed under the Company's profile on SEDAR at www.sedar.com from time to time. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management on the date of this new release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.
SOURCE: Helix BioPharma Corp.
View source version on accesswire.com:
https://www.accesswire.com/693267/Helix-Biopharma-Corp-Announces-Unexpected-Passing-of-Interim-CEO-and-Chairman-of-the-Board
